Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

LL-37 Research: Pathogen Type Comparison

Understanding how LL-37 performs across different pathogen classes guides experimental design and application selection. The following comparison synthesizes published MIC data, mechanism distinctions, and research model performance. Gram-negative bacteria 2–1

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Understanding how LL-37 performs across different pathogen classes guides experimental design and application selection. The following comparison synthesizes published MIC data, mechanism distinctions, and research model performance.
  • Gram-negative bacteria
  • 2–16 μg/mL (low salt); 8–64 μg/mL (physiological salt)
  • Membrane disruption + LPS neutralization
  • Antibiotic resistance, sepsis, biofilm studies
  • Salt sensitivity reduces efficacy in serum-based assays
  • Excellent for mucosal/epithelial models; moderate for systemic infection
  • Gram-positive bacteria
  • 2–8 μg/mL
  • Membrane disruption + peptidoglycan binding
  • MRSA, Streptococcus, antibiotic synergy
  • Protease degradation in tissue environments
  • High efficacy; strong candidate for combination therapy research
  • Enveloped viruses
  • 10–40 μg/mL (IC50 for entry inhibition)
  • Envelope disruption + GAG receptor competition
  • Influenza, RSV, HSV, HIV entry studies
  • Requires high concentrations; limited post-entry activity
  • Promising for prophylaxis research; less viable for established infection
  • Fungal pathogens
  • 8–32 μg/mL
  • Membrane disruption + biofilm interference
  • Candida biofilms, invasive aspergillosis
  • Higher MICs than bacteria; toxicity concerns at therapeutic doses
  • Valuable for biofilm research; topical applications more feasible
  • Biofilm-embedded bacteria
  • 8–64 μg/mL (2–4× planktonic MIC)
  • Biofilm penetration + matrix disruption
  • Device-associated infections, chronic wounds
  • Concentration-dependent toxicity limits in vivo dosing
  • Superior to conventional antibiotics for biofilm penetration research